US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

LB Pharmaceuticals Inc. (LBRX): Clubby Deal Expected in Thursday's Schizophrenia Biotech IPO

LB Pharmaceuticals Inc. (LBRX): Strong Open, Schizophrenia Biotech Finds Early Momentum

LB Pharmaceuticals Inc. (LBRX): Peeking at the IPO Prospectus of Schizophrenia Product Candidate Bio

IPOs and Secondary Offerings

Equity Capital Markets

LB Pharmaceuticals / Equity Capital Markets

<ul>
<li>LB Pharmaceuticals is offering 16.7 million shares at $14-$16 equating to a market cap of $281m-$322m.</li>
<li>According to guidance that the deal is well-oversubscribed at launch from a comprehensive testing-the-waters meetings.</li>
<li>Investor sentiment toward the subsector remains constructive, and the company’s lead candidate is entering Phase III with a solid track record of clinical data.</li>
</ul>


LB Pharmaceuticals is offering 16.7 million shares at $14-$16 equating to a market cap of $281m-$322m.
According to guidance that the deal is well-oversubscribed at launch from a comprehensive testing-the-waters meetings.
Investor sentiment toward the subsector remains constructive, and the company’s lead candidate is entering Phase III with a solid track record of clinical data.


LB Pharmaceuticals Inc. (LBRX): Schizophrenia Biotech Sets Terms, Readies for Same-Week Debut